NuCana (NCNA) Non Operating Interest Expenses (2025)

NuCana (NCNA) reported Non Operating Interest Expenses of -$16.9 million for Q2 2025.

NuCana (NCNA) Non Operating Interest Expenses (2025) Analysis & Trends

NuCana (NCNA) has 1 years of Non Operating Interest Expenses data on file, last reported at -$16.9 million in Q2 2025.

For the quarter ending Q2 2025, Non Operating Interest Expenses changed N/A year-over-year to -$16.9 million; the trailing twelve-month figure through Dec 2025 stood at -$16.9 million (changed N/A YoY), and the FY2025 full-year result was -$16.7 million, changed N/A from the prior year.
Non Operating Interest Expenses steadied at -$16.9 million in Q2 2025.
In the past five years, Non Operating Interest Expenses ranged from a high of -$16.9 million in Q2 2025 to a low of -$16.9 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Interest Expenses (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-220,921.81
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	NuCana	14.60 Bn	14.60 Bn	-	-

Download Data

Date	Value
Jun 30, 2025	-16.87 Mn